|
Schirdewan博士的引述的參考文獻: ' A2 S) B" N1 C; ^/ d
" @3 `: X1 O: C9 l+ {
Camm, AJ et al., Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation (透過Home Monitoring技術遠距控制植入式裝置可改進房顫的檢測和臨床管理), Europace, 11(1):54–61, 2009.
6 J9 Z& x( @+ e( N) S
7 W! v7 O8 R7 F- mDaubert, JP et al., Inappropriate implantable cardioverter-defibrillator shocks in MADIT-II (MADIT-II中植入式心臟複律去顫器不合時宜的電擊), JACC, 51:1357–65, 2008
8 I: Y. I% y6 U
" `7 v9 Z0 ]( _2 }, ^8 b) mRicci, RP et al., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (心房顫動管理指南:歐洲心臟學會心房顫動管理工作小組), Europace, 12(10):1360–1420, 2010. , _! W; I- L/ N3 m& D
: {! ^' @. c& p! O8 {3 I" w. r
關於BIOTRONIK SE & Co. KG) K. F3 }$ e" P
" ~' I" L/ l7 K: q4 o
BIOTRONIK公司是世界領先的心血管醫療器材製造商之一,已售出數百萬台植入式裝置,全球員工超過5600位,業務遍及100多個國家。BIOTRONIK公司密切感知醫療界的脈動、評估醫生面臨的挑戰,從診斷、治療到患者管理,為患者醫護的所有階段提供最佳解決方案。BIOTRONIK公司及其不斷成功的理念在於品質、創新和可靠性,從而為全球醫生及其患者帶來信心和安心。進一步資訊請瀏覽: www.biotronik.com |
|